Trial on MRI-guided SBRT for Liver Metastases Aims to Establish Safe Dose Levels
This clinical trial aims to establish safe dose levels for MRI-guided SBRT in treating liver metastases, which could significantly influence treatment protocols in oncology. The outcomes may enhance the competitive positioning of companies involved in advanced radiation therapies.
AutoResearch
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/13/2026, 6:00:18 AM
Assessment confidence: 65% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
Executive Thesis
This clinical trial aims to establish safe dose levels for MRI-guided SBRT in treating liver metastases, which could significantly influence treatment protocols in oncology. The outcomes may enhance the competitive positioning of companies involved in advanced radiation therapies. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (10 high-relevance).
Strategic Assessment
Success in establishing safe dose levels may enhance treatment options and market positioning for companies involved in radiation therapy. The strongest clinical anchor is Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (ClinicalTrials.gov), patient population match (advanced). In Oncology · Radiation Therapy, 7 regulatory and 4 competitive items passed relevance filtering for radiation therapy companies.
Competitive Pressure
The most relevant competitive pressure comes from Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma (Humanexa Signals) — patient population match (advanced). Secondary pressure from MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated. This trial could provide insights into the safety and efficacy of advanced radiation techniques, impacting competitive positioning in oncology treatments.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — ONTRUZANT (SUPPL) (FDA). Regulatory pathway relevance (bla). Relevant agencies in corpus: FDA, MHRA. Establishing safe dose levels could facilitate regulatory approvals for new treatment protocols, thereby influencing compliance and market entry strategies.
Key Risks
- Elevated medium regulatory exposure for radiation therapy companies could delay market entry or constrain labeling if agency review intensifies.
- Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on radiation therapy companies through agency review timelines and labeling constraints if follow-through weakens.
Key Opportunities
- If successful, this trial could lead to new treatment options that may capture market share in the oncology sector, impacting revenue streams for companies involved in radiation therapy.
- Oncology · Melanoma · Trial Update · This trial introduces a novel combination therapy that could enhance treatment options for patients with advanced melanoma, potentially impacting the competitive landscape for existing therapies.
- Oncology · Oropharyngeal Cancer · Trial Update · This trial could provide insights into more precise radiotherapy techniques, potentially influencing treatment standards in oropharyngeal cancer.
- Upside for radiation therapy companies may improve if Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer (ClinicalTrials.gov) delivers favorable follow-through.
- Success in establishing safe dose levels may enhance treatment options and market positioning for companies involved in radiation therapy.
What Would Change This Assessment
- This becomes more urgent if Monitor the trial's progress and results for potential shifts in treatment protocols and competitive dynamics in oncology.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — ONTRUZANT (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View sourceFDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View sourceFDA AP — HERCEPTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View sourceSunscreen: How to Help Protect Your Skin from the Sun
FDAhigh relevance
Moderate corpus alignment
FDA document
View sourceClass 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View sourceOAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceLiver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceStudy on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respir
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTrial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma
Humanexa Signalshigh relevance
Patient population match (advanced)
MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated
Humanexa Signalsmedium relevance
Moderate corpus alignment
Pridopidine Phase 3 Trial Initiated for ALS Efficacy and Safety Evaluation
Humanexa Signalsmedium relevance
Moderate corpus alignment
Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors
Humanexa Signalsmedium relevance
Moderate corpus alignment
Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceImmunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceSafety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceFEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Regunera
Precedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitiva
Competitors · threats
Loading competitive findings…
View full competitive analysisWhy this matters
This clinical trial aims to establish safe dose levels for MRI-guided SBRT in treating liver metastases, which could significantly influence treatment protocols in oncology. The outcomes may enhance the competitive positioning of companies involved in advanced radiation therapies.
Affected entities
- radiation therapy companies
- oncology treatment protocols
- clinical trial participants
Commercial impact
If successful, this trial could lead to new treatment options that may capture market share in the oncology sector, impacting revenue streams for companies involved in radiation therapy.
Regulatory impact
Establishing safe dose levels could facilitate regulatory approvals for new treatment protocols, thereby influencing compliance and market entry strategies.
What to watch
Monitor the trial's progress and results for potential shifts in treatment protocols and competitive dynamics in oncology.
Recommended action
Track for follow-up milestones; no immediate action required.